BURNETT JOSEPH sold $33K of CLPT (indirect holdings)

BURNETT JOSEPH (CEO and President) sold 1,843 indirectly-held shares of ClearPoint Neuro, Inc. (CLPT) at $17.94 on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BURNETT JOSEPH
Published Jun 22, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLPT
Neutral
high confidence
Mentioned
$CLPT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLPTNeutralLow
01

Why it matters

The newest disclosed fact is the June 17 open-market sale of 1,843 shares by CEO Joseph Burnett under a 10b5-1 plan, with post-sale holdings reported.

02

Market read

Primarily useful for tracking insider activity; likely limited trading impact absent additional company-specific catalysts.

03

What to watch

The sale is indirect and on a pre-arranged plan; without context on total planned volume and prior filings, the signal strength is uncertain.

Relevance 2/10Novelty 3/10Timing: Filed June 22 after the June 17 sale; relevant for monitoring insider-flow sentiment.

Background

The article is an SEC Form 4 insider transaction disclosure for ClearPoint Neuro, Inc. (CLPT).

Company-level read

Ticker impact

$CLPTNeutralHigh confidence
Context

ClearPoint Neuro CEO Joseph Burnett filed a Form 4 selling 1,843 shares at $17.94 on a 10b5-1 plan, reducing holdings to 191,388.

Expected impact

Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 nature.

Evidence & confidence

The filing is a disclosed insider transaction with a stated pre-arranged 10b5-1 plan; there is no accompanying operational, financial, or regulatory development in the text.

Market effects

Minimal—this is company-specific insider transaction data with no sector-wide read-across provided.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with periods of perceived valuation risk; traders may still watch for follow-on selling volume or clustering of insider actions.

Key entities

  • ClearPoint Neuro, Inc.

    Company whose Form 4 insider transaction is disclosed (CLPT).

  • Joseph Burnett

    CEO and President; reported an indirect open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLPTMed

ClearPoint Neuro (CLPT) Q3 2026 Earnings Call Transcript

ClearPoint Neuro (CLPT) reported Q3 2026 revenue of $12.1M, up 36% YoY, driven by growth in neurosurgery navigation and capital equipment sales. The company used its ATM facility to raise $22M, ending the quarter with $46.2M in cash. CLPT supports uniQure's BLA submission for Huntington's disease treatment, aiming for parallel FDA approvals. The company is preparing for increased Phase III trials and commercial product launches in 2027.

$CLPTMed

What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call

ClearPoint Neuro (CLPT) reported Q3 operating expenses of $13.4M, down from $17M in Q2. Cash reserves were $46.2M, with $22M raised via equity offering. CEO Burnett expects reduced operating burn and capital expenditures. The company awaits FDA decision on AMT-130 submission, with potential parallel approvals for drug and device. ClearPoint outlined four growth pillars, including biologics, neurosurgery navigation, and laser therapy.

$CLPTMed

ClearPoint Neuro Reports Third Quarter 2026 Results

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offerin